The emerging genetic and molecular basis of Fanconi anaemia - PubMed (original) (raw)
Review
The emerging genetic and molecular basis of Fanconi anaemia
H Joenje et al. Nat Rev Genet. 2001 Jun.
Abstract
The past few years have witnessed a considerable expansion in our understanding of the pathways that maintain chromosome stability in dividing cells through the identification of genes that are mutated in certain human chromosome instability disorders. Cells that are derived from patients with Fanconi anaemia (FA) show spontaneous chromosomal instability and mutagen hypersensitivity, but FA poses a unique challenge as the nature of the DNA-damage-response pathway thought to be affected by the disease has long been a mystery. However, the recent cloning of most of the FA-associated genes, and the characterization of their protein products, has provided tantalizing clues as to the molecular basis of this disease.
Similar articles
- The Fanconi anaemia/BRCA pathway.
D'Andrea AD, Grompe M. D'Andrea AD, et al. Nat Rev Cancer. 2003 Jan;3(1):23-34. doi: 10.1038/nrc970. Nat Rev Cancer. 2003. PMID: 12509764 Review. - Direct interaction of the Fanconi anaemia protein FANCG with BRCA2/FANCD1.
Hussain S, Witt E, Huber PA, Medhurst AL, Ashworth A, Mathew CG. Hussain S, et al. Hum Mol Genet. 2003 Oct 1;12(19):2503-10. doi: 10.1093/hmg/ddg266. Epub 2003 Aug 5. Hum Mol Genet. 2003. PMID: 12915460 - Fanconi anaemia and leukaemia - clinical and molecular aspects.
Tischkowitz M, Dokal I. Tischkowitz M, et al. Br J Haematol. 2004 Jul;126(2):176-91. doi: 10.1111/j.1365-2141.2004.05023.x. Br J Haematol. 2004. PMID: 15238138 Review. - The Fanconi Anemia/BRCA pathway: new faces in the crowd.
Kennedy RD, D'Andrea AD. Kennedy RD, et al. Genes Dev. 2005 Dec 15;19(24):2925-40. doi: 10.1101/gad.1370505. Genes Dev. 2005. PMID: 16357213 Review. - [From gene to disease: Fanconi anemia].
Zwaan CM, Joenje H. Zwaan CM, et al. Ned Tijdschr Geneeskd. 2003 Feb 22;147(8):342-4. Ned Tijdschr Geneeskd. 2003. PMID: 12661120 Review. Dutch.
Cited by
- RFWD3 modulates response to platinum chemotherapy and promotes cancer associated phenotypes in high grade serous ovarian cancer.
Taylor SJ, Hollis RL, Gourley C, Herrington CS, Langdon SP, Arends MJ. Taylor SJ, et al. Front Oncol. 2024 Apr 22;14:1389472. doi: 10.3389/fonc.2024.1389472. eCollection 2024. Front Oncol. 2024. PMID: 38711848 Free PMC article. - FANCA facilitates G1/S cell cycle advancement, proliferation, migration and invasion in gastric cancer.
Wang W, Baral S, Liu B, Sun Q, Wang L, Ren J, Tang D, Wang D. Wang W, et al. Acta Biochim Biophys Sin (Shanghai). 2024 Apr 29;56(7):973-985. doi: 10.3724/abbs.2024045. Acta Biochim Biophys Sin (Shanghai). 2024. PMID: 38682160 Free PMC article. - Fanconi Anemia: A Rare Genetic Disorder.
Thakur B, Hiwale KM. Thakur B, et al. Cureus. 2023 May 11;15(5):e38899. doi: 10.7759/cureus.38899. eCollection 2023 May. Cureus. 2023. PMID: 37303314 Free PMC article. - DNA Damage and Its Role in Cancer Therapeutics.
Moon J, Kitty I, Renata K, Qin S, Zhao F, Kim W. Moon J, et al. Int J Mol Sci. 2023 Mar 1;24(5):4741. doi: 10.3390/ijms24054741. Int J Mol Sci. 2023. PMID: 36902170 Free PMC article. Review. - The RPA inhibitor HAMNO sensitizes Fanconi anemia pathway-deficient cells.
Jang SW, Kim JM. Jang SW, et al. Cell Cycle. 2022 Jul;21(14):1468-1478. doi: 10.1080/15384101.2022.2074200. Epub 2022 May 11. Cell Cycle. 2022. PMID: 35506981 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous